ID   PLPL9_RAT               Reviewed;         807 AA.
AC   P97570; G3V7M8; Q66HD1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2012, sequence version 2.
DT   02-OCT-2024, entry version 171.
DE   RecName: Full=85/88 kDa calcium-independent phospholipase A2;
DE            Short=CaI-PLA2;
DE            EC=3.1.1.4 {ECO:0000269|PubMed:18937505, ECO:0000269|PubMed:9111008};
DE   AltName: Full=2-lysophosphatidylcholine acylhydrolase;
DE            EC=3.1.1.5 {ECO:0000250|UniProtKB:O60733};
DE   AltName: Full=Group VI phospholipase A2;
DE            Short=GVI PLA2;
DE   AltName: Full=Intracellular membrane-associated calcium-independent phospholipase A2 beta;
DE            Short=iPLA2-beta;
DE   AltName: Full=Palmitoyl-CoA hydrolase;
DE            EC=3.1.2.2 {ECO:0000269|PubMed:18937505};
DE   AltName: Full=Patatin-like phospholipase domain-containing protein 9;
DE            Short=PNPLA9;
GN   Name=Pla2g6; Synonyms=Pnpla9;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), FUNCTION, CATALYTIC ACTIVITY,
RP   ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Pancreatic islet;
RX   PubMed=9111008; DOI=10.1074/jbc.272.17.11250;
RA   Ma Z., Ramanadham S., Kempe K., Chi X.S., Ladenson J., Turk J.;
RT   "Pancreatic islets express a Ca2+-independent phospholipase A2 enzyme that
RT   contains a repeated structural homologous to the integral membrane protein
RT   binding domain of ankyrin.";
RL   J. Biol. Chem. 272:11118-11127(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RA   Mural R.J., Li P.W., Adams M.D., Amanatides P.G., Baden-Tillson H.,
RA   Barnstead M., Chin S.H., Dew I., Evans C.A., Ferriera S., Flanigan M.,
RA   Fosler C., Glodek A., Gu Z., Holt R.A., Jennings D., Kraft C.L., Lu F.,
RA   Nguyen T., Nusskern D.R., Pfannkoch C.M., Sitter C., Sutton G.G.,
RA   Venter J.C., Wang Z., Woodage T., Zheng X.H., Zhong F.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ACTIVITY REGULATION, AND CALMODULIN-BINDING REGIONS.
RX   PubMed=11118454; DOI=10.1074/jbc.m010439200;
RA   Jenkins C.M., Wolf M.J., Mancuso D.J., Gross R.W.;
RT   "Identification of the calmodulin-binding domain of recombinant calcium-
RT   independent phospholipase A2beta. implications for structure and
RT   function.";
RL   J. Biol. Chem. 276:7129-7135(2001).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND ACTIVITY REGULATION.
RX   PubMed=18937505; DOI=10.1021/bi800923s;
RA   Carper M.J., Zhang S., Turk J., Ramanadham S.;
RT   "Skeletal muscle group VIA phospholipase A2 (iPLA2beta): expression and
RT   role in fatty acid oxidation.";
RL   Biochemistry 47:12241-12249(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [8]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=24648512; DOI=10.1074/jbc.m114.561910;
RA   Song H., Wohltmann M., Tan M., Ladenson J.H., Turk J.;
RT   "Group VIA phospholipase A2 mitigates palmitate-induced beta-cell
RT   mitochondrial injury and apoptosis.";
RL   J. Biol. Chem. 289:14194-14210(2014).
CC   -!- FUNCTION: Calcium-independent phospholipase involved in phospholipid
CC       remodeling with implications in cellular membrane homeostasis,
CC       mitochondrial integrity and signal transduction. Hydrolyzes the ester
CC       bond of the fatty acyl group attached at sn-1 or sn-2 position of
CC       phospholipids (phospholipase A1 and A2 activity respectively),
CC       producing lysophospholipids that are used in deacylation-reacylation
CC       cycles (PubMed:18937505, PubMed:9111008). Hydrolyzes both saturated and
CC       unsaturated long fatty acyl chains in various glycerophospholipid
CC       classes such as phosphatidylcholines, phosphatidylethanolamines and
CC       phosphatidates, with a preference for hydrolysis at sn-2 position. Can
CC       further hydrolyze lysophospholipids carrying saturated fatty acyl
CC       chains (lysophospholipase activity) (PubMed:18937505). Upon oxidative
CC       stress, contributes to remodeling of mitochondrial phospholipids in
CC       pancreatic beta cells, in a repair mechanism to reduce oxidized lipid
CC       content (PubMed:24648512). Preferentially hydrolyzes oxidized
CC       polyunsaturated fatty acyl chains from cardiolipins, yielding
CC       monolysocardiolipins that can be reacylated with unoxidized fatty acyls
CC       to regenerate native cardiolipin species. Hydrolyzes oxidized
CC       glycerophosphoethanolamines present in pancreatic islets, releasing
CC       oxidized polyunsaturated fatty acids such as hydroxyeicosatetraenoates
CC       (HETEs) (PubMed:24648512). Has thioesterase activity toward fatty-acyl
CC       CoA releasing CoA-SH known to facilitate fatty acid transport and beta-
CC       oxidation in mitochondria particularly in skeletal muscle
CC       (PubMed:18937505). Plays a role in regulation of membrane dynamics and
CC       homeostasis. Selectively hydrolyzes sn-2 arachidonoyl group in
CC       plasmalogen phospholipids, structural components of lipid rafts and
CC       myelin (By similarity). Regulates F-actin polymerization at the
CC       pseudopods, which is required for both speed and directionality of
CC       MCP1/CCL2-induced monocyte chemotaxis (By similarity). Targets membrane
CC       phospholipids to produce potent lipid signaling messengers. Generates
CC       lysophosphatidate (LPA, 1-acyl-glycerol-3-phosphate), which acts via G-
CC       protein receptors in various cell types. Has phospholipase A2 activity
CC       toward platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-
CC       3-phosphocholine), likely playing a role in inactivation of this potent
CC       pro-inflammatory signaling lipid (By similarity). In response to
CC       glucose, amplifies calcium influx in pancreatic beta cells to promote
CC       INS secretion (By similarity). {ECO:0000250|UniProtKB:A0A3L7I2I8,
CC       ECO:0000250|UniProtKB:O60733, ECO:0000250|UniProtKB:P97819,
CC       ECO:0000269|PubMed:18937505, ECO:0000269|PubMed:24648512,
CC       ECO:0000269|PubMed:9111008}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000269|PubMed:18937505, ECO:0000269|PubMed:9111008};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15802;
CC         Evidence={ECO:0000305|PubMed:18937505, ECO:0000305|PubMed:9111008};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:41223, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41224;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + H2O = (9Z)-octadecenoate + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + H(+); Xref=Rhea:RHEA:38779, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30823, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73001; Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38780;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+); Xref=Rhea:RHEA:40811,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30245,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73002;
CC         Evidence={ECO:0000269|PubMed:18937505, ECO:0000269|PubMed:9111008};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40812;
CC         Evidence={ECO:0000305|PubMed:18937505, ECO:0000305|PubMed:9111008};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:40427, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:72998, ChEBI:CHEBI:73003;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40428;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         octadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:40519, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:73858, ChEBI:CHEBI:74965;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40520;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphoethanolamine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphoethanolamine + H(+);
CC         Xref=Rhea:RHEA:40431, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:73004, ChEBI:CHEBI:73009;
CC         Evidence={ECO:0000250|UniProtKB:P97819};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40432;
CC         Evidence={ECO:0000250|UniProtKB:P97819};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphate + H2O = 1-
CC         hexadecanoyl-sn-glycero-3-phosphate + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:63304, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57518, ChEBI:CHEBI:72859;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63305;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + H2O = a fatty acid +
CC         H(+) + sn-glycerol 3-phosphocholine; Xref=Rhea:RHEA:15177,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:16870,
CC         ChEBI:CHEBI:28868, ChEBI:CHEBI:58168; EC=3.1.1.5;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15178;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = H(+) +
CC         hexadecanoate + sn-glycerol 3-phosphocholine; Xref=Rhea:RHEA:40435,
CC         ChEBI:CHEBI:7896, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16870, ChEBI:CHEBI:72998;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40436;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine
CC         + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + sn-glycerol 3-
CC         phosphocholine; Xref=Rhea:RHEA:40831, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16870, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:74344; Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40832;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine
CC         + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + sn-glycerol 3-
CC         phosphocholine; Xref=Rhea:RHEA:40827, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16870, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:76079; Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40828;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-
CC         phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-O-
CC         hexadecyl-sn-glycero-3-phosphocholine + H(+); Xref=Rhea:RHEA:41067,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:55430, ChEBI:CHEBI:64496;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41068;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         O-hexadecyl-sn-glycero-3-phosphocholine + acetate + H(+);
CC         Xref=Rhea:RHEA:40479, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:44811, ChEBI:CHEBI:64496;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40480;
CC         Evidence={ECO:0000250|UniProtKB:A0A3L7I2I8};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + hexadecanoyl-CoA = CoA + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:16645, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379; EC=3.1.2.2;
CC         Evidence={ECO:0000269|PubMed:18937505};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16646;
CC         Evidence={ECO:0000305|PubMed:18937505};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1',3'-bis[1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho]-
CC         glycerol + H2O = (9Z)-octadecenoate + 1'-[1,2-di-(9Z-octadecenoyl)-
CC         sn-glycero-3-phospho]-3'-[1-(9Z-octadecenoyl)-sn-glycero-3-phospho]-
CC         glycerol + H(+); Xref=Rhea:RHEA:40463, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30823, ChEBI:CHEBI:77253,
CC         ChEBI:CHEBI:77259; Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40464;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1'-[1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho]-3'-[1-(9Z-
CC         octadecenoyl)-sn-glycero-3-phospho]-glycerol + H2O = (9Z)-
CC         octadecenoate + 1',3'-bis-[1-(9Z-octadecenoyl)-sn-glycero-3-phospho]-
CC         glycerol + H(+); Xref=Rhea:RHEA:40467, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30823, ChEBI:CHEBI:77256,
CC         ChEBI:CHEBI:77259; Evidence={ECO:0000250|UniProtKB:O60733};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40468;
CC         Evidence={ECO:0000250|UniProtKB:O60733};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1',3'-bis-[1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phospho]-glycerol + H2O = (9Z,12Z)-octadecadienoate + 1'-[1,2-di-
CC         (9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho]-3'-[1-(9Z,12Z-
CC         octadecadienoyl)-sn-glycero-3-phospho]-glycerol + H(+);
CC         Xref=Rhea:RHEA:52812, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:83580, ChEBI:CHEBI:83581;
CC         Evidence={ECO:0000269|PubMed:24648512};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:52814;
CC         Evidence={ECO:0000305|PubMed:24648512};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(15-hydroxy-(5Z,8Z,11Z,13E)-
CC         eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-
CC         octadecanoyl-sn-glycero-3-phosphoethanolamine + 15-hydroxy-
CC         (5Z,8Z,11Z,13E)-eicosatetraenoate + H(+); Xref=Rhea:RHEA:63256,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:75036,
CC         ChEBI:CHEBI:78832, ChEBI:CHEBI:146277;
CC         Evidence={ECO:0000269|PubMed:24648512};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63257;
CC         Evidence={ECO:0000305|PubMed:24648512};
CC   -!- ACTIVITY REGULATION: Activated by ATP (PubMed:18937505,
CC       PubMed:9111008). Inhibited by calcium-activated calmodulin
CC       (PubMed:11118454, PubMed:18937505). Inhibited by bromoenol lactone
CC       (BEL) (PubMed:18937505). {ECO:0000269|PubMed:11118454,
CC       ECO:0000269|PubMed:18937505, ECO:0000269|PubMed:9111008}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7. {ECO:0000269|PubMed:9111008};
CC   -!- SUBUNIT: Homodimer formed by catalytic domains tightly interacting
CC       through a large hydrophobic interface. The contact area involves 3
CC       alpha helices, several loops and a part of the beta sheet from each
CC       monomer. Both active sites of the dimer are in close proximity adopting
CC       an open conformation that provide sufficient space for phospholipid
CC       access and favoring cooperativity in deacylation-reacylation reactions.
CC       Each monomer has 9 ankyrin repeats stacked side-by-side in an elongated
CC       structure oriented outwards from the catalytic core.
CC       {ECO:0000250|UniProtKB:A0A3L7I2I8}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:O60733}. Cell
CC       membrane {ECO:0000250|UniProtKB:O60733}. Mitochondrion
CC       {ECO:0000250|UniProtKB:P97819}. Cell projection, pseudopodium
CC       {ECO:0000250|UniProtKB:O60733}. Note=Recruited to the membrane-enriched
CC       pseudopods upon MCP1/CCL2 stimulation in monocytes.
CC       {ECO:0000250|UniProtKB:O60733}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P97570-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P97570-2; Sequence=VSP_044365;
CC   -!- TISSUE SPECIFICITY: Expressed in pancreatic beta-cells
CC       (PubMed:9111008). Expressed in skeletal muscle (at protein level)
CC       (PubMed:18937505). {ECO:0000269|PubMed:18937505,
CC       ECO:0000269|PubMed:9111008}.
CC   -!- DOMAIN: Has two putative calmodulin binding domains, the 1-9-14 and IQ
CC       motifs (PubMed:11118454). One calmodulin molecule interacts with PLA2G6
CC       dimer, likely through 1-9-14 motif on each monomer (By similarity).
CC       Binds calmodulin in a calcium-dependent way (PubMed:11118454).
CC       {ECO:0000250|UniProtKB:A0A3L7I2I8, ECO:0000269|PubMed:11118454}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U51898; AAC53136.1; -; mRNA.
DR   EMBL; AABR06052011; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473950; EDM15808.1; -; Genomic_DNA.
DR   EMBL; CH473950; EDM15809.1; -; Genomic_DNA.
DR   EMBL; BC081916; AAH81916.1; -; mRNA.
DR   RefSeq; NP_001005560.1; NM_001005560.1. [P97570-1]
DR   RefSeq; NP_001257725.1; NM_001270796.1. [P97570-2]
DR   AlphaFoldDB; P97570; -.
DR   SMR; P97570; -.
DR   IntAct; P97570; 1.
DR   STRING; 10116.ENSRNOP00000072104; -.
DR   ChEMBL; CHEMBL1075318; -.
DR   iPTMnet; P97570; -.
DR   PhosphoSitePlus; P97570; -.
DR   PaxDb; 10116-ENSRNOP00000017104; -.
DR   GeneID; 360426; -.
DR   KEGG; rno:360426; -.
DR   UCSC; RGD:628867; rat. [P97570-1]
DR   AGR; RGD:628867; -.
DR   CTD; 8398; -.
DR   RGD; 628867; Pla2g6.
DR   VEuPathDB; HostDB:ENSRNOG00000012295; -.
DR   eggNOG; KOG0513; Eukaryota.
DR   HOGENOM; CLU_010817_0_0_1; -.
DR   InParanoid; P97570; -.
DR   OrthoDB; 518048at2759; -.
DR   PhylomeDB; P97570; -.
DR   TreeFam; TF319230; -.
DR   Reactome; R-RNO-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-RNO-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-RNO-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-RNO-6811436; COPI-independent Golgi-to-ER retrograde traffic.
DR   PRO; PR:P97570; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Proteomes; UP000234681; Chromosome 7.
DR   Bgee; ENSRNOG00000012295; Expressed in testis and 20 other cell types or tissues.
DR   GO; GO:0005615; C:extracellular space; ISO:RGD.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031143; C:pseudopodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0003847; F:1-alkyl-2-acetylglycerophosphocholine esterase activity; ISS:UniProtKB.
DR   GO; GO:0043008; F:ATP-dependent protein binding; IDA:RGD.
DR   GO; GO:0047499; F:calcium-independent phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0052816; F:long-chain fatty acyl-CoA hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0004622; F:lysophospholipase activity; ISS:UniProtKB.
DR   GO; GO:0004623; F:phospholipase A2 activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0017171; F:serine hydrolase activity; ISO:RGD.
DR   GO; GO:0019731; P:antibacterial humoral response; ISO:RGD.
DR   GO; GO:0035965; P:cardiolipin acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0032049; P:cardiolipin biosynthetic process; ISO:RGD.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEP:RGD.
DR   GO; GO:0007613; P:memory; IMP:RGD.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0046473; P:phosphatidic acid metabolic process; ISS:UniProtKB.
DR   GO; GO:0034638; P:phosphatidylcholine catabolic process; ISS:UniProtKB.
DR   GO; GO:0046338; P:phosphatidylethanolamine catabolic process; ISS:UniProtKB.
DR   GO; GO:0046469; P:platelet activating factor metabolic process; ISS:UniProtKB.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; IDA:RGD.
DR   GO; GO:2000304; P:positive regulation of ceramide biosynthetic process; IDA:RGD.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:RGD.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IDA:RGD.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IMP:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:RGD.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:RGD.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:RGD.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IMP:RGD.
DR   GO; GO:0042311; P:vasodilation; IMP:RGD.
DR   CDD; cd07212; Pat_PNPLA9; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 3.40.1090.10; Cytosolic phospholipase A2 catalytic domain; 1.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR047148; PLPL9.
DR   InterPro; IPR002641; PNPLA_dom.
DR   PANTHER; PTHR24139:SF34; 85_88 KDA CALCIUM-INDEPENDENT PHOSPHOLIPASE A2; 1.
DR   PANTHER; PTHR24139; CALCIUM-INDEPENDENT PHOSPHOLIPASE A2; 1.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF01734; Patatin; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 6.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF52151; FabD/lysophospholipase-like; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS51635; PNPLA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ANK repeat; Calmodulin-binding; Cell membrane;
KW   Cell projection; Chemotaxis; Cytoplasm; Hydrolase; Lipid metabolism;
KW   Membrane; Mitochondrion; Phospholipid metabolism; Phosphoprotein;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix.
FT   CHAIN           1..807
FT                   /note="85/88 kDa calcium-independent phospholipase A2"
FT                   /id="PRO_0000067039"
FT   TRANSMEM        481..501
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        512..532
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REPEAT          120..147
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000250|UniProtKB:A0A3L7I2I8"
FT   REPEAT          151..181
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          185..215
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          219..248
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          251..281
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          286..312
FT                   /note="ANK 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          316..345
FT                   /note="ANK 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          349..378
FT                   /note="ANK 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          382..403
FT                   /note="ANK 9"
FT                   /evidence="ECO:0000250|UniProtKB:A0A3L7I2I8"
FT   DOMAIN          482..666
FT                   /note="PNPLA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   REGION          678..687
FT                   /note="Calmodulin-binding (1-9-14 motif)"
FT                   /evidence="ECO:0000269|PubMed:11118454"
FT   REGION          749..760
FT                   /note="Calmodulin-binding (IQ motif)"
FT                   /evidence="ECO:0000269|PubMed:11118454"
FT   MOTIF           486..491
FT                   /note="GXGXXG"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   MOTIF           518..522
FT                   /note="GXSXG"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   MOTIF           653..655
FT                   /note="DGA/G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   ACT_SITE        520
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   ACT_SITE        653
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01161"
FT   MOD_RES         13
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   VAR_SEQ         396..451
FT                   /note="LITRKALLTLLKTVGADYHFPFIQGVSTEQSSAAGPHPFFSLDRTQPPTISL
FT                   NNLE -> Q (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:9111008"
FT                   /id="VSP_044365"
FT   CONFLICT        24
FT                   /note="V -> A (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="V -> D (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        68
FT                   /note="G -> D (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="A -> V (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        99
FT                   /note="V -> E (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109
FT                   /note="Missing (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        142
FT                   /note="S -> T (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477
FT                   /note="S -> T (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        793
FT                   /note="H -> Y (in Ref. 1; AAC53136)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   807 AA;  89556 MW;  1B9018AE1B2D252F CRC64;
     MQFFGRLVNT LSSVTNLFSN PFRVKEVSLA DYASSERVRE EGQLILLQNA SNRTWDCVLV
     SPRNPQSGFR LFQLESEADA LVNFQQYSSQ LPPFYESSVQ VLHVEVLQHL TDLIRNHPSW
     TVTHLAVELG IRECFHHSRI ISCANSTENE EGCTPLHLAC RKGDSEILVE LVQYCHAQMD
     VTDNKGETAF HYAVQGDNPQ VLQLLGKNAS AGLNQVNNQG LTPLHLACQM GKQEMVRVLL
     LCNARCNIMG PGGFPIHTAM KFSQKGCAEM IISMDSNQIH SKDPRYGASP LHWAKNAEMA
     RMLLKRGCDV DSTSASGNTA LHVAVTRNRF DCVMVLLTYG ANAGARGEHG NTPLHLAMSK
     DNMEMVKALI VFGAEVDTPN DFGETPAFIA SKISKLITRK ALLTLLKTVG ADYHFPFIQG
     VSTEQSSAAG PHPFFSLDRT QPPTISLNNL ELQDLMPVSR ARKPAFILSS MRDEKRSHDH
     LLCLDGGGVK GLVIIQLLIA IEKASGVATK DLFDWVAGTS TGGILALAIL HSKSMAYMRG
     VYFRMKDEVF RGSRPYESGP LEEFLKREFG EHTKMTDVKK PKVMLTGTLS DRQPAELHLF
     RNYDAPEAVR EPRCTPNINL KPPTQPADQL VWRAARSSGA APTYFRPNGR FLDGGLLANN
     PTLDAMTEIH EYNQDMIRKG QGNKVKKLSI VVSLGTGKSP QVPVTCVDVF RPSNPWELAK
     TVFGAKELGK MVVDCCTDPD GRAVDRARAW CEMVGIQYFR LNPQLGSDIM LDEVSDAVLV
     NALWETEVYI YEHREEFQKL VQLLLSP
//
